Effect of HMGCoA reductase inhibitors on cytochrome P450 expression in endothelial cell line

被引:22
作者
Bertrand-Thiebault, Celine [1 ]
Masson, Christine [1 ]
Siest, Gerard [1 ]
Batt, Anne-Marie [1 ]
Visvikis-Siest, Sophie [1 ]
机构
[1] Univ Nancy 1, U525, Equipe 4, Fac Pharm,INSERM, F-54000 Nancy, France
关键词
arachidonic acid; cytochrome P450; nuclear receptors; statins;
D O I
10.1097/FJC.0b013e31803e8756
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Endothelial cells and smooth muscle cells are the major cells that constitute blood vessels, and endothelial cells line the lumen of blood vessels. These 2 types of cells also play an integral role in the regional specialization of vascular structure. On the basis of these observations, we designed our study to investigate the effect of various statins on CYP expression in endothelial cells. 3-hydroxymethyl coenzyme A reductase inhibitors play an important role in vascular function. The majority of the statins available on the market show extensive metabolism by cytochrome P450 (CYP) enzymes. Both cell types are involved in the bioconversion of arachidonic acid into vasoactive compounds. The aim of this study was to demonstrate the effect of statins on cytochrome P450 expression in endothelial cells. Our results show that endothelial cells expressed both CYPs involved in epoxyeicosatrienoic acids (EETs) and hydroxyeicosatetraenoic acids (HETEs) production and the nuclear receptor implicated in cytochrome P450 regulation. Treatment of endothelial cells with lovastatin increased CYP2C9 expression. After 96 hours of treatment, fluvastatin and lovastatin clearly increased CYP2C9 protein level. CAR but not PXR was expressed in endothelial cells, indicating that the upregulating effect of statins on CYP2C9 in endothelial cells could be mediated through CAR only due to the lack of expression of PXR in these cells.
引用
收藏
页码:306 / 315
页数:10
相关论文
共 49 条
[1]   Hypercholesterolemia, lipid-lowering agents, and the risk for brain infarction [J].
Amarenco, P .
NEUROLOGY, 2001, 57 (05) :S35-S44
[2]   Cytochrome P450 1B1:: A major P450 isoenzyme in human blood monocytes and macrophage subsets [J].
Baron, JM ;
Zwadlo-Klarwasser, G ;
Jugert, F ;
Hamann, W ;
Rübben, A ;
Mukhtar, H ;
Merk, HF .
BIOCHEMICAL PHARMACOLOGY, 1998, 56 (09) :1105-1110
[3]  
Beaird S L, 2000, J Am Pharm Assoc (Wash), V40, P637
[4]  
Bellosta S, 2000, DIABETES CARE, V23, pB72
[5]   Cytochromes P450 are differently expressed in normal and varicose human saphenous veins: Linkage with varicosis [J].
Bertrand-Thiebault, C ;
Ferrari, L ;
Boutherin-Falson, O ;
Kockx, M ;
Desquand-Billiald, S ;
Fichelle, JM ;
Nottin, R ;
Renaud, JF ;
Batt, AM ;
Visvikis, S .
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2004, 31 (5-6) :295-301
[6]   Critical evaluation of ECV304 as a human endothelial cell model defined by genetic analysis and functional responses: A comparison with the human bladder cancer derived epithelial cell line t24/83 [J].
Brown, J ;
Reading, SJ ;
Jones, S ;
Fitchett, CJ ;
Howl, J ;
Martin, A ;
Longland, CL ;
Michelangeli, F ;
Dubrova, YE ;
Brown, CA .
LABORATORY INVESTIGATION, 2000, 80 (01) :37-45
[7]   Endothelium-derived hyperpolarizing factors and vascular cytochrome P450 metabolites of arachidonic acid in the regulation of tone [J].
Campbell, WB ;
Harder, DR .
CIRCULATION RESEARCH, 1999, 84 (04) :484-488
[8]  
Chen H, 2000, DRUG METAB DISPOS, V28, P1051
[9]   Endothelial cell diversity revealed by global expression profiling [J].
Chi, JT ;
Chang, HY ;
Haraldsen, G ;
Jahnsen, FL ;
Troyanskaya, OG ;
Chang, DS ;
Wang, Z ;
Rockson, SG ;
Van de Rijn, M ;
Botstein, D ;
Brown, PO .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (19) :10623-10628
[10]   Clinically relevant differences between the statins: Implications for therapeutic selection [J].
Chong, PH ;
Seeger, JD ;
Franklin, C .
AMERICAN JOURNAL OF MEDICINE, 2001, 111 (05) :390-400